Skip to main content

infliximab

 

Status: One Wales interim decision

Using the agreed starting and stopping criteria, infliximab can be made available within NHS Wales for the treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other immunosupressants.

Infliximab should be prescribed on the basis of lowest acquisition cost.

The risks and benefits of the off-label use of infliximab for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

This advice will be reviewed after 12 months or earlier if new evidence becomes available.

 One Wales Interim Decision with rationale and start stop criteria infliximab for pulmonary sarcoidosis. OW23. 2023. (PDF, 129Kb)
 Evidence status report. Infliximab in refractory pulmonary sarcoidosis. OW23. 2022. (PDF, 283Kb)

Medicine details

Medicine name infliximab
Formulation infusion
Reference number OW23
Indication

Treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other immunosupressants

Company various
BNF chapter Respiratory system
Submission type One Wales
Status One Wales interim decision
Advice number OW23
Date of issue 02/03/2023
Follow AWTTC: